Ignite Creation Date:
2024-05-06 @ 12:45 PM
Last Modification Date:
2024-10-26 @ 1:03 PM
Study NCT ID:
NCT03840824
Status:
COMPLETED
Last Update Posted:
2020-02-11
First Post:
2015-03-17
Brief Title:
Blood Spot Self-administered Test and Assay
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
Blood Spot Self-administered Test and Assay
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The current study will compare hormone levels of AMH FSH and inhibin B in blood specimens collected by venipuncture and fingerstick in a sample of pre-menopausal women ages 18-45 years with normal menstrual cycles
Detailed Description:
Recent advances in cancer diagnosis and treatment have led to greater survival rates in patients with malignancies However these life-saving treatments especially alkylating agents often lead to premature ovarian failure infertility and related long-term health problems It is difficult to predict whether and the extent to which patients will experience these problems There are no early clinical signs of decreased fertility potential even young women who maintain cyclic menses after therapy are at high risk of infertility early menopause and related health problems Preliminary studies suggest that several surrogate measures of fertility potential are different in cancer survivors compared with controls These include follicle stimulating hormone FSH estradiol anti-mullerian hormone AMH and inhibin B Large longitudinal studies are needed to validate these measures with gold standard outcomes such as pregnancy rates pregnancy outcomes and time to menopause The main impediment to assessing the value of these markers and generating data that is useful to cancer survivors is the need for frequent and timed blood samples
Daily or frequent trips to the clinical center are not practical and reduce the compliance of even the most motivated patients The hypothesis that will be tested by this study is that blood spot assays can be developed that provide robust personalized data for surrogate markers of reproductive function which can be used to assess reproductive potential in women furthermore bloodspots collected at home are an acceptable method for reproductive hormone measurement in women with and without a history of cancer The current study will compare hormone levels of AMH FSH and inhibin B in blood specimens collected by venipuncture and fingerstick in a sample of subjects
Daily or frequent trips to the clinical center are not practical and reduce the compliance of even the most motivated patients The hypothesis that will be tested by this study is that blood spot assays can be developed that provide robust personalized data for surrogate markers of reproductive function which can be used to assess reproductive potential in women furthermore bloodspots collected at home are an acceptable method for reproductive hormone measurement in women with and without a history of cancer The current study will compare hormone levels of AMH FSH and inhibin B in blood specimens collected by venipuncture and fingerstick in a sample of subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None